Aardvark Therapeutics, Inc. (AARD)
NASDAQ:AARD
Want to see AARD full AI Analyst Report?
AARD Stock Chart & Stats
$5.23
--
Market closed
$5.23
--
Day’s Range― - ―
52-Week Range$3.35 - $17.94
Previous CloseN/A
VolumeN/A
Average Volume (3M)166.37K
Market Cap
$117.59M
Enterprise Value$73.81M
Total Cash (Recent Filing)$110.03M
Total Debt (Recent Filing)$441.00K
Price to Earnings (P/E)―
Beta2.31
Next Earnings
May 20, 2026EPS Estimate
-0.88Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.81
Shares Outstanding21,816,042
10 Day Avg. Volume148,283
30 Day Avg. Volume166,372
Financial Highlights & Ratios
PEG Ratio-0.05
Price to Book (P/B)2.42
Price to Sales (P/S)0.00
P/FCF Ratio-4.75
Enterprise Value/Market Cap0.63
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit-3.69K
Enterprise Value/Ebitda-1.20
Forecast
1Y Price Target
$13.26Price Target Upside153.51% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering9
EPS Forecast (FY)-3.45
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Cash RunwayThe company reports a cash position expected to support ongoing operations, which reduces immediate financing pressure and provides time to address the safety signal.
Dose OptimizationAnalysis indicates the heart electrical changes were reversible and linked to higher drug exposure, suggesting lower dosing could avoid the issue and allow the program to continue if regulators accept a reduced-dose approach.
Trial Design And Early ReadoutPausing the pivotal study could permit early unblinding that may reveal efficacy signals from enrolled patients and help design a streamlined subsequent registration study.
Bears Say
Clinical Program DisruptionA voluntary pause of the pivotal program and other trials removed key upcoming catalysts and will delay availability of pivotal results while investigations are completed.
Regulatory UncertaintyRegulators are highly sensitive to heart-related findings for chronic weight treatments, increasing uncertainty around approval and potentially complicating efforts to restart trials.
Safety Risk In Target PopulationThe drug’s target is present in heart tissue and reversible cardiac effects in healthy volunteers raise concern that the therapeutic window may be limited, particularly for patients with cardiovascular comorbidities.
Aardvark Therapeutics, Inc. News
AARD FAQ
What was Aardvark Therapeutics, Inc.’s price range in the past 12 months?
Aardvark Therapeutics, Inc. lowest stock price was $3.35 and its highest was $17.94 in the past 12 months.
What is Aardvark Therapeutics, Inc.’s market cap?
Aardvark Therapeutics, Inc.’s market cap is $117.59M.
When is Aardvark Therapeutics, Inc.’s upcoming earnings report date?
Aardvark Therapeutics, Inc.’s upcoming earnings report date is May 20, 2026 which is in 22 days.
How were Aardvark Therapeutics, Inc.’s earnings last quarter?
Aardvark Therapeutics, Inc. released its earnings results on Apr 06, 2026. The company reported -$0.81 earnings per share for the quarter, beating the consensus estimate of -$0.827 by $0.017.
Is Aardvark Therapeutics, Inc. overvalued?
According to Wall Street analysts Aardvark Therapeutics, Inc.’s price is currently Undervalued.
Does Aardvark Therapeutics, Inc. pay dividends?
Aardvark Therapeutics, Inc. does not currently pay dividends.
What is Aardvark Therapeutics, Inc.’s EPS estimate?
Aardvark Therapeutics, Inc.’s EPS estimate is -0.88.
How many shares outstanding does Aardvark Therapeutics, Inc. have?
Aardvark Therapeutics, Inc. has 21,816,042 shares outstanding.
What happened to Aardvark Therapeutics, Inc.’s price movement after its last earnings report?
Aardvark Therapeutics, Inc. reported an EPS of -$0.81 in its last earnings report, beating expectations of -$0.827. Following the earnings report the stock price went down -2.179%.
Which hedge fund is a major shareholder of Aardvark Therapeutics, Inc.?
Currently, no hedge funds are holding shares in AARD
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Aardvark Therapeutics, Inc. Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$13.26 (153.51% Upside)
$13.26 (153.51% Upside)
Crowd Wisdom
Negative
Last 7 Days ▲ 0.3%
Last 30 Days ▼ 1.0%
Last 30 Days ▼ 1.0%
Fundamentals
Return on Equity
-44.59%
Trailing 12-Months
Asset Growth
51.19%
Trailing 12-Months
Company Description
Aardvark Therapeutics, Inc.
Aardvark Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing small-molecule therapeutics to activate innate homeostatic pathways for the treatment of metabolic diseases. Its lead product candidate is the ARD-101, an oral gut-restricted small-molecule agonist of certain targeting bitter taste receptors expressed in the gut lumen that is in Phase III clinical trial for hyperphagia associated with Prader-Willi Syndrome, as well as in Phase II clinical trial for hyperphagia associated with acquired hypothalamic obesity resultant from treatment of craniopharyngioma, including surgery or radiation. It also developing ARD-201, which is in Phase I clinical trial for the treatment of obesity. The company was incorporated in 2017 and is based in San Diego, California.
AARD Stock 12 Month Forecast
Average Price Target
$13.26
▲(153.51% Upside)
Technical Analysis
Ownership Overview
14.98% Insiders
4.39% Mutual Funds
<0.01% Other Institutional Investors
74.95% Public Companies and Individual Investors